Shukra Pharmaceuticals Ltd. conducted its mandatory independent directors meeting on March 16, 2026, fulfilling regulatory requirements under the Securities and Exchange Board of India (LODR) Regulations, 2015, and the Companies Act, 2013.

Meeting Details and Compliance

The meeting was held at the company's registered office and lasted for 30 minutes, commencing at 1:00 PM and concluding at 1:30 PM. This gathering was organized pursuant to Regulation 25(3) of the SEBI (LODR) Regulations, 2015, read with Schedule IV of the Companies Act, 2013, specifically for the Financial Year 2025-26.

Key Agenda Items Reviewed

The independent directors addressed several critical governance matters during their session:

Governance and Performance Assessment

The independent directors conducted a comprehensive evaluation of the company's governance structure. They reviewed the performance of non-independent directors and assessed the overall effectiveness of the board of directors. Additionally, they evaluated the chairperson's performance, taking into account perspectives from both executive and non-executive directors.

Information Flow Evaluation

A significant focus of the meeting was assessing the information flow between the company's management and the board of directors. The independent directors evaluated whether the quality, quantity, and timeliness of information provided enables the board to effectively and reasonably perform their duties.

Regulatory Communication

The outcome of this meeting was formally communicated to BSE Limited's Department of Corporate Services, with the notification signed by Director Ritu Kapoor (DIN: 1033424). This communication ensures compliance with disclosure requirements under Regulation 30 of the SEBI (LODR) Regulations, 2015.

Shukra Pharmaceuticals Limited has announced outstanding financial results for the third quarter and nine months ended December 31, 2025, showcasing remarkable growth across key performance metrics. The pharmaceutical company's Board of Directors approved these unaudited results during their meeting held on February 4, 2026, pursuant to Regulation 30 and 33 of SEBI Listing Regulations.

Exceptional Quarterly Performance with Strong EBITDA Growth

The company delivered stellar results for Q3FY26, with significant improvements across all major financial parameters. Revenue from operations witnessed substantial growth, while profitability metrics showed exceptional enhancement compared to the previous year. The EBITDA performance was particularly noteworthy, demonstrating the company's operational efficiency.

Strong Nine-Month Performance

The nine-month period ended December 31, 2025, demonstrated consistent growth momentum with impressive year-on-year improvements. The company maintained its growth trajectory across revenue and profitability metrics.

Operational Efficiency and Cost Management

The company demonstrated effective cost management during the quarter. Total expenses for Q3FY26 stood at ₹131.19 crores compared to ₹74.96 crores in Q3FY25. Key expense components included cost of materials consumed at ₹32.00 crores, employee benefit expenses of ₹26.47 crores, and other expenses totaling ₹22.17 crores.

For the nine-month period, total expenses reached ₹256.36 crores against ₹162.93 crores in the corresponding period last year, reflecting the company's expanded operations and business growth.

Board Meeting and Regulatory Compliance

The Board meeting commenced at 3:30 PM and concluded at 4:00 PM on February 4, 2026, at the company's registered office. The directors reviewed the company's business operations and approved the quarterly results in accordance with SEBI regulations. The statutory auditors Shah Sanghvi & Associates provided an unqualified opinion on the financial results.

Regulatory Publication Requirements

Pursuant to Regulation 47 of SEBI Listing Obligations and Disclosure Requirements Regulations 2015, the company published its unaudited financial results in designated newspapers on February 5, 2026. The results were published in Business Standard (English) and Jai Hind (Gujarati) newspapers to ensure compliance with regulatory requirements and provide transparency to stakeholders.

Leadership Continuity

The Board approved the re-appointment of Mr. Dakshesh Shah as Managing Director for a five-year term from December 30, 2025, to December 30, 2030. Mr. Shah brings over 30 years of extensive experience across pharmaceuticals, infrastructure, finance, hospitality, healthcare, and entertainment sectors.